Merck Signs a Clinical Trial Collaboration with Xilio for Anti-CTLA-4 Monoclonal Antibody Program
Shots:
- The companies collaborated to evaluate XTX101 + Keytruda for patients with solid tumors. The planned P-I study will be conducted by Xilio and is designed to evaluate the safety & efficacy of XTX101 as a monothx. and in combination with Keytruda for solid tumors
- Xilio plans to submit an IND for XTX101 to the US FDA in Q2’21. Following the IND clearance- Xilio expects to initiate a P-I study. In preclinical studies- XTX101 was well-tolerated and achieved robust tumor growth inhibition
- XTX101 is a tumor-selective anti-CTLA-4 mAb designed to pinpoint the anti-CTLA-4 effect geographically within the tumor without off-tumor peripheral effects
Ref: Businesswire | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com